Back to results
US 2010/0137334 A1Published application
Piperidine and Piperazine Derivatives
AssigneeM's Science Corporation
InventorsConnie L. Sun, Xiaoyuan Li
Life of this patent
Estimating the term…
Abstract
Compounds of general formula (Ia): in which R1, A1, m, X, n, Y and R3 have any of the meanings given in the specification, have affinity for sigma receptors and are useful in the treatment of disorders of the central nervous system.
Claims21
A compound of general formula (Ia)
- in which:—
- R1 represents 2,3-dihydrobenzofuran-5-yl or a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-6C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkylsulfonyl group, a halo(1-4C)alkoxy group and a halo(1-4C)alkylsulfonyl group;
- A1 represents (CH2)m or (CH2)m-1C(═O);
- m is 2, 3, 4 or 5;
- X is CH or N;
- n is 0, 1, 2, 3, 4 or 5, provided that when X is N, n is 2, 3, 4 or 5;
- Y is O, NR2 or S;
- R2 is hydrogen, (1-4C)alkyl or phenyl(1-4C)alkyl, or is as defined for R3;
- and
- R3 represents indan-1-yl, indan-2-yl, 1,2,3,4-tetrahydronaphth-1-yl or 1,2,3,4-tetrahydronaphth-2-yl, each of which may bear a hydroxyl substituent on a non-aromatic carbon atom;
- (3-6C) cycloalkyl;
- or a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a cyano group;
- a phenyl group, an imidazolyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group and a halo(1-4C)alkoxy group;
- or a pharmaceutically acceptable salt thereof,
- but excluding the compounds 1-[2-phenoxyethyl]-4-[phenylacetyl]piperazine and 1-[3-(3,4-dichlorophenoxy)propyl]-4-[(4-chlorophenyl)acetyl]piperazine.
12 more elements
A method of treating a condition responsive to a modulator of sigma receptor function in a patient requiring treatment, which comprises administering to said patient an effective amount of a compound of general formula (Ia)
- in which:—
- R1 represents 2,3-dihydrobenzofuran-5-yl or a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-6C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkylsulfonyl group, a halo(1-4C)alkoxy group and a halo(1-4C)alkylsulfonyl group;
- A1 represents (CH2)m or (CH2)m-1C(═O);
- m is 2, 3, 4 or 5;
- X is CH or N;
- n is 0, 1, 2, 3, 4 or 5, provided that when X is N, n is 2, 3, 4 or 5;
- Y is O, NR2 or S;
- R2 is hydrogen, (1-4C)alkyl or phenyl(1-4C)alkyl, or is as defined for R3;
- and
- R3 represents indan-1-yl, indan-2-yl, 1,2,3,4-tetrahydronaphth-1-yl or 1,2,3,4-tetrahydronaphth-2-yl, each of which may bear a hydroxyl substituent on a non-aromatic carbon atom;
- (3-6C) cycloalkyl;
- or a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a cyano group;
- a phenyl group, an imidazolyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group and a halo(1-4C)alkoxy group;
- or a pharmaceutically acceptable salt thereof.
11 more elements
Use of a compound a compound of general formula (Ia)
- in which:—
- R1 represents 2,3-dihydrobenzofuran-5-yl or a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a cyano group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a halo(1-4C) alkyl group, a (1-6C)alkoxy group, a (1-4C)alkoxy(1-4C)alkoxy group, a hydroxy(1-4C)alkoxy group, a (1-4C)alkylsulfanyl group, a (1-4C)alkyl)sulfonyl group, a halo(1-4C)alkoxy group and a halo(1-4C)alkylsulfonyl group;
- A1 represents (CH2)in or (CH2)m-1C(═O);
- m is 2, 3, 4 or 5;
- X is CH or N;
- n is 0, 1, 2, 3, 4 or 5, provided that when X is N, n is 2, 3, 4 or 5;
- Y is O, NR2 or S;
- R2 is hydrogen, (1-4C)alkyl or phenyl(1-4C)alkyl, or is as defined for R3;
- and
- R3 represents indan-1-yl, indan-2-yl, 1,2,3,4-tetrahydronaphth-1-yl or 1,2,3,4-tetrahydronaphth-2-yl, each of which may bear a hydroxyl substituent on a non-aromatic carbon atom;
- (3-6C) cycloalkyl;
- or a phenyl group that is unsubstituted or substituted by one, two or three substituents selected independently from (1-2C)alkylenedioxy, a halogen atom, a hydroxyl group, a (1-4C) alkyl group, a (3-6C)cycloalkyl group, a cyano group;
- a phenyl group, an imidazolyl group, a halo(1-4C) alkyl group, a (1-4C)alkoxy group and a halo(1-4C)alkoxy group;
- or a pharmaceutically acceptable salt thereof,
- in the manufacture of a medicament for the treatment of a condition responsive to a modulator of sigma receptor function.
12 more elements
Dependencies are inferred from the claim text.